Updated Jul 16, 2026 · Last SEC filing 2026-07-09
RECURSION PHARMACEUTICALS, INC. (RXRX) has filed 23 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-09. 3 Form 8-K material event filings were reported by RXRX in the last 90 days. 22 Form 144 notices of proposed sale were filed for RXRX stock. InsiderAlpha tracks every RXRX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001601830 |
| Form 4 filings (90d) | 23 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 22 |
| Latest Form 4 filing | 2026-07-09 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director | S — Open-market sale | 40.0K | $3.96 | $158K | SEC | |
| Li Dean Y | Director | A — Grant or award | 3.7K | $0.00 | — | SEC | |
| Dar Zavain | Director | A — Grant or award | 5.1K | $0.00 | — | SEC | |
| Bumpus Namandje | Director | S — Open-market sale | 4.0K | $3.18 | $13K | SEC | |
| Li Dean Y | Director | A — Grant or award | 88.4K | $0.00 | — | SEC | |
| Dar Zavain | Director | A — Grant or award | 88.4K | $0.00 | — | SEC | |
| Sun Elaine D | Director | A — Grant or award | 88.4K | $0.00 | — | SEC | |
| HERSHBERG ROBERT | Director | A — Grant or award | 88.4K | $0.00 | — | SEC | |
| Borgeson Blake | Director | A — Grant or award | 88.4K | $0.00 | — | SEC | |
| Michor Franziska | Director | A — Grant or award | 88.4K | $0.00 | — | SEC | |
| Bumpus Namandje | Director | A — Grant or award | 88.4K | $0.00 | — | SEC | |
| Taylor Ben R | Chief Financial Officer | F — Tax withholding / forfeiture | 5.4K | $3.15 | $17K | SEC | |
| Gibson Christopher | Director | S — Open-market sale | 40.0K | $3.62 | $145K | SEC | |
| Gibson Christopher | Director | J — Other acquisition / disposition | 40.0K | $0.00 | — | SEC | |
| Khan Najat | CEO and President | S — Open-market sale | 23.6K | $3.58 | $84K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for RECURSION PHARMACEUTICALS, INC. (RXRX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Gibson Christopher | 14 | $617K |
| Borgeson Blake | 4 | $374K |
| Bumpus Namandje | 3 | $28K |
| Khan Najat | 2 | $275K |
| Dar Zavain | 2 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RXRX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live RXRX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.